Abstract: Provided herein are penicillin expandase mutants, DNA coding the mutants, reagent kit containing the mutants and the application. The penicillin expandase mutants using SEQ ID NO.: 2 in the Sequence Listing as a reference sequence, have at least one amino acid mutation at residue positions corresponding to threonine at position 42 and glutamine at position 126, wherein, amino acid at position 42 is substituted by any other natural amino acid except threonine, amino acid at position 126 is substituted by any other natural amino acid except glutamine. The penicillin expandase mutants of present invention have increased its thermostability and catalytic activity; it is more suitable for commercial and industrial applications.

Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.

Abstract: The present invention relates to compositions and methods for the improvement of bakery products, in particular for the improvement of the texture of cakes and the tolerance of bakery doughs.

Abstract: Animal feed or animal feed additives comprising one or more polypeptides having lysozyme activity are disclosed. Polypeptides having lysozyme activity, polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides are also provided.

Abstract: The invention relates to compositions comprising at least one protease and at least one biosurfactant, particularly selected from rhamnolipids and sophorolipids. In particular, the present invention is directed to a composition including A) at least one peptidase, B) at least one biosurfactant, and optionally C) at least one anionic surfactant. The peptidase may be selected from the group of the proteases, particularly from the group of the serine proteases of EC 3.4.21 and the metalloproteases of EC 3.4.24 and the biosurfactant may be selected from the group comprising rhamnolipids and sophorolipids.

Abstract: The present invention relates to mammalian cells modified to provide for improved expression of a recombinant protein of interest. In particular, the invention relates to CHO cells and other host cells in which the expression of one or more endogenous secreted proteins has been disrupted, as well as to the preparation, identification and use of such cells in the production of recombinant proteins.

Abstract: The invention relates to a long-chain dibasic acid with low content of monobasic acid impurity and a production method thereof, in particular to the preparation of a long-chain dibasic acid producing strain by means of directed evolution and homologous recombination, and to the production of a long-chain dibasic acid with low content of monobasic acid impurity by fermentation of said strain. The invention relates to a mutated CYP52A12 gene, homologous gene or variant thereof, which, relative to GenBank Accession Number AY230498 and taking the first base upstream of the start codon ATG as ?1, comprises a mutation. The invention relates to a strain comprising said mutated CYP52A12 gene, homologous gene or variant thereof wherein when the strain is fermented to produce a long-chain dibasic acid, the content of monobasic acid impurity in the fermentation product is significantly reduced.

Abstract: The present invention discloses an industrial scale method to obtain 1-kestose by the use of a recombinant fructosyltransferase (FTF), isolated from Festuca arundinacea, expressed constitutively in a non-saccharolytic yeast. In this invention, the recombinant FTF type sucrose:sucrose 1-fructosyltransferase (1-SSTrec) is produced constitutively, stable and at high yield, both in the culture supernatant and in intact cells of the host Pichia pastoris. Hence, the invention additionally provides a method for 1-SST production at industrial scale. The recombinant enzyme is then used for mass production of short-chain fructooligosaccharides (FOS), specifically 1-kestose, from sucrose. The method of the present invention establishes conditions that allow conversion rates where the synthesized FOS constitute above 55% (w/w) of the total sugars in the reaction mixture and the 1-kestose content reaches values higher than 90% (w/w) of the total FOS fraction.

Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.

Abstract: The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms by engineering a microorganism for increased carbon flux towards mevalonate production in the following enzymatic pathways: (a) citrate synthase, (b) phosphotransacetylase, (c) acetate kinase, (d) lactate dehydrogenase, (e) malic enzyme, and (f) pyruvate dehydrogenase such that one of more of the enzyme activity is modulated. In addition, production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids can be further enhanced by the heterologous expression of the mvaE and mvaS genes (such as, but not limited to, mvaE and mvaS genes from the organisms Listeria grayi DSM 20601, Enterococcus faecium, Enterococcus gallinarum EG2, and Enterococcus casseliflavus).

Abstract: The present invention relates to a protein having glucose dehydrogenase activity selected from: (a) an amino acid sequence represented by SEQ ID NO: 3; (b) an amino acid sequence in which 1 to 3 amino acids are deleted from, replaced in or added to the amino acid sequence represented by SEQ ID NO: 3; (c) an amino acid sequence which has at least 80% identity with the amino acid sequence represented by SEQ ID NO: 3 and whose N-terminus is SS; or (d) an amino acid sequence which has at least 80% identity with the amino acid sequence represented by SEQ ID NO: 3, and does not contain a sequence represented by SEQ ID NO: 8 at its N-terminus. The invention also includes a polynucleotide encoding the enzyme, a method for manufacturing the enzyme, a method for measuring glucose using the enzyme, a measuring reagent composition and a biosensor.

Abstract: The invention relates to pharmaceutical compositions comprising a conjugate of a porphyrin (e.g., PpIX) and a recombinant protein. The pharmaceutical compositions of the invention may be used in photodynamic therapy. The invention also relates to methods of producing such pharmaceutical compositions and to methods of using such pharmaceutical compositions in the treatment of diseases, such as cancer.

Abstract: The present invention relates to processes for producing ethanol from lignocellulosic hydrolysates comprising, hexoses, pentoses and acetic acid, whereby genetically modified yeast cells are use that comprise an exogenous gene encoding an acetaldehyde dehydrogenase and a bacterial gene encoding an enzyme with NAD+-linked glycerol dehydrogenase activity. The process is further characterised in that glycerol is present in or fed into the culture medium, whereby the modified yeast cell ferments the hexoses, pentoses, acetic acid and glycerol to ethanol. The invention further relates to yeast cells for use in such processes. The yeast cells advantageously comprise genetic modifications that improve glycerol utilization such as modifications that increase one or more of dihydroxyacetone kinase activity and transport of glycerol into the cell.

Abstract: The present invention relates to the production of aromatic hexanols and compositions containing them. In particular provided herein are methods of producing hexenols comprising: a) contacting a hydroperoxide of a polyunsaturated fatty acid with a modified hydroperoxide lyase to form a hexenal; and b) reducing the hexenal to a hexenol in the presence of a hydride donor, a ketoreductase, and a co-factor wherein the contacting and reducing steps are carried out at essentially the same time in the substantial absence of baker's yeast.

Abstract: Described is a method for the production isoamyl alcohol (3-methylbutan-1-ol) comprising the enzymatic conversion of 3-methylbutyryl-CoA (isovaleryl-CoA) into isoamyl alcohol comprising: (a) two enzymatic steps comprising (i) first the enzymatic conversion of 3-methylbutyryl-CoA into 3-methylbutyraldehyde (3-methylbutanal or isovaleraldehyde); and (ii) then enzymatically converting the thus obtained 3-methylbutyraldehyde into said isoamyl alcohol; or (b) a single enzymatic reaction in which 3-methylbutyryl-CoA is directly converted into isoamyl alcohol by making use of an alcohol-forming short chain acyl-CoA dehydrogenase/fatty acyl-CoA reductase or an alcohol-forming fatty acyl-CoA reductase (long-chain acyl-CoA:NADPH reductase) (EC 1.2.1.84). Further, described is the above method wherein the 3-methylbutyryl-CoA can be provided by the enzymatic conversion of 3-methylcrotonyl-CoA into said 3-methylbutyryl-CoA.

Abstract: The present invention relates to a method for improving the heterologous synthesis of a polyketide by E. coli and use thereof. The yield of the polyketide heterologously synthesized by E. coli is significantly increased by attenuating the expression of seventy-two genes, such as sucC and talB, in a host strain, wherein the highest yield increase rate can reach 60% or more. Currently, erythromycin is the most clear model compound in the study on the biosynthesis of polyketids. The production strain of the present invention enables massive accumulation of 6-deoxyerythronolide (6-dEB), an erythromycin precursor, in the fermentation process, laying the foundation for the industrial production of the heterologous synthesis of erythromycin by E. coli.

Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having one or more modifications as compared to a parent lipolytic enzyme having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.

Abstract: The present invention relates to a novel recombinant batroxobin mixture, a hemostatic composition comprising the same, and a method for preparing the same. According to the present invention, the hemostatic composition of the present invention has an excellent hemostatic effect by suppressing rebleeding, and maintains activity thereof even when prepared in a solid form, and thus, the composition of the present invention can be easily used by being applied as a topical hemostatic agent.

Abstract: The present invention provides for a genetically modified host cell or bacterium capable of producing an organic molecule, wherein the bacterium is capable of using hydrogen sulfide as an electron donor, carbon dioxide (CO2) as a carbon source, and/or nitrate as an electron acceptor. The present invention is useful in the wastewater treatment industry, in particular in municipal wastewater treatment plants (WWTP).

Abstract: The present invention provides a novel fluorescent protein. A novel protein includes the following protein (F1): (F1) a protein consisting of an amino acid sequence of SEQ ID NO: 1, wherein in the amino acid sequence of SEQ ID NO: 1, a 52nd amino acid Xaa52 is an arbitrary amino acid, a 133rd amino acid Xaa133 is an arbitrary amino acid, and a 154th amino acid Xaa154 is an arbitrary amino acid.